Hepatitis B surface antigen and liver function markers as diagnostic parameters for Iraq patients infected with Hepatitis B virus.

Abstract

Background: The infection of Hepatitis B virus  represents a significant global health challenge with a serious complexities like the failure of liver and hepatocellular carcinoma. It results in an estimated mortality of  1.12 million case in 2022. Aim of Study: This study aims to examine and explore the status and the tests of serology and biochemical of liver functions in patients of HBV in Wasit Province, Iraq. Materials and Methods: This study involved 75 patients, both male and female, made up the study population. Hepatitis B virus (HBV)-positive patients' samples were gathered from Al-Karama Teaching Hospitals and the General Public Health Central lab in Kut city between December 2023 and May 2024 and versus same number of healthy individuals as control.  The enzymatic liver biomarkers (the ALT, the AST, the ALP, and the TSB) were detected by utilizing the Roche Cobas C111 system and Hepatitis B surface antigen  was detected by utilizing the ELISA . Results: Based on the study's findings the liver enzymes showed a significant and a remarkably rising among group of patients. Conclusion: The paper of research  gives insight as the utilizing of ELISA is much more effective  and it could be used in monitoring the progress of HBV infection along with liver enzymes. It also concluded that there is a higher correlation between HBV-DAN level, and elevated  levels of enzymes like the ALT, the AST, the ALP, and the TSB. These increased levels of enzymes may be playing a potential diagnostic and prognostic value in HBV-related liver dysfunction.